Latest Data Shaping the CELMoD Landscape

Program Overview

This conference coverage activity provides an overview of cereblon E3 ligase modulators (CELMoDs), including their mechanism of action and the evolving role of these novel agents in the treatment of multiple myeloma. Expert faculty review the current clinical development of iberdomide and mezigdomide, with a detailed discussion of recently presented efficacy and safety data on iberdomide from major international hematology meetings. The program concludes with a discussion between multiple myeloma expert Dr. Nisha Joseph and community hematologist/oncologist Dr. Samantha Shams, who examine the potential place of CELMoDs within future treatment algorithms and discuss considerations for integrating these emerging therapies into community practice.

Target Audience

This educational series is intended to provide continuing medical education (CME)/continuing education (CE) to health care clinicians involved in the treatment of hematologic malignancies, especially multiple myeloma (MM), including medical oncologists, hematologists, hematology/oncology (hem/onc) fellows, and advanced practice providers (APPs).

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Summarize the most recent clinical trial data on investigational therapies for MM, such as the novel CELMoD treatments, emerging from recent hematology/oncology conferences
2. Discuss where novel CELMoD therapies would fit into future treatment algorithms for MM
3. Describe strategies for incorporating CELMoD therapy into personalized medicine approaches in MM, based on the latest clinical data and potential future FDA-approval

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Nisha Joseph, MD:

• Consulting Fees: AstraZeneca, Bristol Myers Squibb, Cell Centriq, GSK, J&J Oncology, Legend, Pfizer, Regeneron

Samantha R. Shams, MD: 

• Nothing to disclose. 

The Integritas Communications planners and managers have no relevant financial relationships with ineligible companies to report. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.